News Headlines

  1. Veeda Lifesciences Announces Partnership With Mango Sciences To Bring AI Innovation In Clinical Trials Services 7/8/2025

    Veeda Lifesciences, a global contract research organization (CRO), has announced an investment in Mango Sciences, a Boston-based healthcare AI and data company.

  2. Lonza Launches Next Generation 4D-Nucleofector LV Unit PRO For Improved Electroporation In GMP Manufacturing 7/7/2025

    Lonza, one of the world’s largest contract development and manufacturing organizations (CDMOs), today announced the launch of 4D-Nucleofector LV Unit PRO, their next-generation large-scale electroporation unit designed to deliver clinically relevant cargos into large volumes of T cells.

  3. UroGen Announces Completion Of Enrollment In The Phase 3 UTOPIA Clinical Trial Of UGN-103 For The Treatment Of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer 7/7/2025

    UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it has completed patient enrollment in its Phase 3 UTOPIA clinical trial of UGN-103 (mitomycin) for intravesical solution, a next-generation formulation in development for the treatment of recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).

  4. Sagent And Qilu Announce Strategic Collaboration To Expand Access To Critical Injectables In U.S. 7/7/2025

    Sagent Pharmaceuticals ("Sagent"), a leading provider of pharmaceuticals to the US market, and Qilu Pharmaceutical Co., Ltd. ("Qilu"), a leading vertically integrated pharmaceutical company based in China, today announced a strategic collaboration to commercialize a portfolio of complex injectable products for the US market.

  5. FF-10832 Granted FDA Orphan Drug Designation For The Treatment Of Biliary Tract Cancer 7/7/2025

    FUJIFILM Pharmaceuticals U.S.A., Inc., drug development center and a leading provider of Contract Development and Manufacturing Organization (CDMO) services for drug delivery system (DDS) technologies, today announced that the U.S.

  6. Almac Completes A Multi-Million-Pound Investment Enhancing Cold Chain Capabilities In Craigavon 7/7/2025

    Almac Clinical Services, part of the Almac Group, has completed a multi-million-pound investment to enhance cold chain capabilities at its global headquarters in Craigavon, Northern Ireland.

  7. Hikma Pharmaceuticals USA Announces $1B Of New US Investment To Further Expand Its Domestic Manufacturing And Development Of Essential Generic Medicines 7/4/2025

    In its ongoing mission to help meet America's growing need for high-quality US-made medicines, Hikma Pharmaceuticals USA today announces it will invest $1 billion by 2030 to further expand its US manufacturing and R&D capabilities.

  8. Biosynth Expands Berlin Site With A New Commercial Bioconjugation Suite 7/3/2025

    Biosynth, a leading developer and supplier of critical raw materials and services for life sciences and diagnostics, is pleased to announce the opening of its expanded GMP bioconjugation facility at its existing Berlin site.

  9. Pace Life Sciences Hosts Grand Opening Of Its Center Of Excellence For Aseptic Fill-Finish Services In Salem, NH 7/2/2025

    Pace® Life Sciences, LLC, a U.S.-based contract research, development, and manufacturing organization (CRDMO) and a Division of Pace®, a Science and Technology Company, builds upon its growth in the pharma and biotech industries by remodeling and expanding its Salem, New Hampshire, site to establish the Center of Excellence for Aseptic Fill-Finish Processing. A grand opening ceremony and open house will be held on July 16, 2025.

  10. CAI And ValGenesis Partner To Deliver AI-Enabled Digital Validation For The Life Sciences Industry 7/1/2025

    CAI, a global professional services firm specializing in operational readiness for regulated industries, today announced a strategic partnership with ValGenesis, Inc., a leader in digital validation lifecycle management. Together, the companies will help life sciences organizations modernize validation processes and improve compliance through the power of artificial intelligence.